Get started
Author

Benga Kazeem

P-396 Characterization and Management of Ocular Events in Patients (Pts) Treated With Belantamab Mafodotin (Belamaf) Plus Bortezomib and Dexamethasone (BVd) in the DREAMM-7 Study
2024 · Vania T.M. Hungria, Pawel Robak, et al. · Clinical Lymphoma Myeloma & Leukemia · 6
Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial
2024 · Vania Hungria, Marek Hus, et al. · Blood · 3
PDF
Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM
2025 · Vania Hungria, Paweł Robak, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
MM-557 DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)
2024 · Maria Victoria, Pawel Robak, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial
2025 · María-Victoria Mateos, Pawel Robak, et al. · Blood · 1
PDF
PA-049 Belantamab Mafodotin, Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Updated 4-Year Results of the Phase 3 DREAMM-7 Trial
2026 · Vania Hungria, Marek Hus, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-196 Extrapolated Progression-Free Survival With Belantamab Mafodotin/Lenalidomide/Dexamethasone (BRd) Exceeds 7 Years in Intermediate-Fit and Frail, Transplant-Ineligible, Newly Diagnosed Multiple Myeloma
2026 · Evangelos Terpos, Maria Gavriatopoulou, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-1168: Belantamab Mafodotin, Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Updated 4-Year Results of the Phase 3 DREAMM-7 Trial
2026 · Robert Rifkin, Vania Hungria, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1168: Belantamab Mafodotin, Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Updated 4-Year Results of the Phase 3 DREAMM-7 Trial
2026 · Robert Rifkin, Vania Hungria, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-1100: Impact of Dose Modifications on Efficacy Outcomes With Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma: Insights From the DREAMM-7 Third-Line or Later Proteasome Inhibitor/Immunomodulatory Agent–Exposed Subgroup
2026 · Al-Ola Abdallah, Abhinav Chandra, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1100: Impact of Dose Modifications on Efficacy Outcomes With Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma: Insights From the DREAMM-7 Third-Line or Later Proteasome Inhibitor/Immunomodulatory Agent–Exposed Subgroup
2026 · Al-Ola Abdallah, Abhinav Chandra, et al. · Clinical Lymphoma Myeloma & Leukemia
Patients with relapsed or refractory multiple myeloma who achieved sustained minimal residual disease negativity in the DREAMM-7 trial
2026 · Mar.a-Victoria Mateos, Paweł Robak, et al. · NCODA Oncology and Hematology Meeting Abstracts
Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis
2025 · Joshua Richter, Meral Beksac, et al. · Blood
Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy
2025 · Attaya Suvannasankha, Benga Kazeem, et al. · Blood
PDF
Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf)–Based Regimens From the DREAMM-7 and DREAMM-8 Trials
2025 · Paweł Robak, Vania Hungria, et al. · Clinical Lymphoma Myeloma & Leukemia
DREAMM-7 Study of Belantamab Mafodotin + Bortezomib (V) + Dexamethasone (d) vs Daratumumab + Vd in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy
2025 · Vania Hungria, Marek Hus, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1034. Characterization of Ophthalmic Examination Findings and Impact on Reading and Driving in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin
2025 · Roman Hájek, Meletios A. Dimopoulos, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1039 Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin-Based Regimens From the Randomized, Phase 3 DREAMM-7 and DREAMM-8 Trials
2025 · Pawel Robak, Vania Hungria, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MM-1049 DREAMM-7 Study of BelantamabMafodotin + Bortezomib + Dexamethasone vs Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy
2025 · Vania Hungria, Marek Hus, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-1049: DREAMM-7 Study of Belantamab Mafodotin + Bortezomib + Dexamethasone vs Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy
2025 · Vania Hungria, Marek Hus, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-1039: Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin-Based Regimens From the Randomized, Phase 3 DREAMM-7 and DREAMM-8 Trials
2025 · Pawel Robak, Vania Hungria, et al. · Clinical Lymphoma Myeloma & Leukemia
DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)
2024 · Maria Victoria Mateos, Pawel Robak, et al. · Clinical Lymphoma Myeloma & Leukemia
Identification of characteristics associated with long-term survival in patients with metastatic urothelial carcinoma (mUC) who received durvalumab (D) with or without tremelimumab (T) in clinical studies.
2021 · Marie Alt, Carlos Stecca, et al. · Journal of Clinical Oncology
Works count: 23
Citation count: 14
H-index: 2
I10-index:
Year
Topic
Type